Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Updates in the treatment of genitourinary cancers

Viktor Grunwald • 25 Oct 2023
ESMO 2023
Genitourinary Cancer Urothelial Carcinoma Antibodies Cisplatin Enfortumab vedotin Gemcitabine Nivolumab Pembrolizumab
EV-302

Viktor Grünwald, MD, PhD, University Hospital Essen, Essen Germany, discusses recent trial findings revealing potential improvements to the treatment of patients with genitourinary cancers, specifically urothelial carcinoma. Dr Grünwald discusses the utilization of nivolumab in standard chemotherapy regimens, and the doublet combination of enfortumab vedotin and pembrolizumab. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Viktor Grunwald

2:14
Treating patients with renal cell cancer in later lines of therapy
Viktor Grunwald • 3 Nov 2023
2:20
Open questions in urothelial carcinoma
Viktor Grunwald • 25 Oct 2023
2:03
Lesion responses to lenvatinib and pembrolizumab based on organ sites
Viktor Grunwald • 25 Oct 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals